Tenet Healthcare Corporation $THC Shares Bought by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt raised its stake in Tenet Healthcare Corporation (NYSE:THC) by 107.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 38,650 shares of the company’s stock after purchasing an additional 20,050 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Tenet Healthcare were worth $7,679,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Wedmont Private Capital raised its holdings in Tenet Healthcare by 2.5% in the fourth quarter. Wedmont Private Capital now owns 2,088 shares of the company’s stock valued at $422,000 after acquiring an additional 50 shares in the last quarter. Baron Wealth Management LLC raised its holdings in Tenet Healthcare by 4.8% during the fourth quarter. Baron Wealth Management LLC now owns 1,142 shares of the company’s stock worth $227,000 after purchasing an additional 52 shares in the last quarter. Sagespring Wealth Partners LLC grew its position in shares of Tenet Healthcare by 3.6% during the fourth quarter. Sagespring Wealth Partners LLC now owns 1,573 shares of the company’s stock worth $313,000 after acquiring an additional 55 shares during the last quarter. Crestwood Advisors Group LLC grew its position in shares of Tenet Healthcare by 2.5% during the third quarter. Crestwood Advisors Group LLC now owns 2,606 shares of the company’s stock worth $529,000 after acquiring an additional 64 shares during the last quarter. Finally, Signaturefd LLC grew its position in shares of Tenet Healthcare by 9.0% during the fourth quarter. Signaturefd LLC now owns 798 shares of the company’s stock worth $159,000 after acquiring an additional 66 shares during the last quarter. Institutional investors and hedge funds own 95.44% of the company’s stock.

Tenet Healthcare Stock Performance

THC stock opened at $160.87 on Friday. The company has a current ratio of 1.36, a quick ratio of 1.30 and a debt-to-equity ratio of 1.96. The firm has a market cap of $13.86 billion, a P/E ratio of 8.37, a P/E/G ratio of 1.08 and a beta of 1.28. Tenet Healthcare Corporation has a 12-month low of $146.60 and a 12-month high of $247.21. The stock’s 50 day simple moving average is $186.93 and its 200 day simple moving average is $201.02.

Tenet Healthcare (NYSE:THC) last posted its quarterly earnings results on Thursday, April 30th. The company reported $4.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.21 by $0.61. The business had revenue of $5.37 billion for the quarter, compared to analyst estimates of $5.39 billion. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The business’s revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company posted $4.36 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. As a group, equities research analysts predict that Tenet Healthcare Corporation will post 17.67 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Paola M. Arbour sold 6,500 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $238.43, for a total transaction of $1,549,795.00. Following the completion of the transaction, the executive vice president owned 29,291 shares of the company’s stock, valued at $6,983,853.13. This trade represents a 18.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Nadja West sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $177.35, for a total value of $532,050.00. Following the transaction, the director directly owned 24,805 shares of the company’s stock, valued at $4,399,166.75. This represents a 10.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 23,138 shares of company stock valued at $4,976,589 over the last three months. 0.97% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

THC has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Tenet Healthcare in a research report on Wednesday, March 4th. Mizuho lifted their price target on Tenet Healthcare from $235.00 to $265.00 and gave the stock an “outperform” rating in a research note on Thursday, March 12th. Barclays cut their target price on shares of Tenet Healthcare from $257.00 to $238.00 and set an “overweight” rating for the company in a research note on Tuesday, May 5th. Royal Bank Of Canada cut their target price on shares of Tenet Healthcare from $277.00 to $236.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Finally, Guggenheim lowered their price target on Tenet Healthcare from $283.00 to $252.00 and set a “buy” rating for the company in a report on Friday, May 1st. Eighteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $244.16.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.